Sugi Predict

Sugi Predict / Compounds / SCHEMBL4498280

SCHEMBL4498280

SCHEMBL4498280

CC1(C)OB(c2ccc(F)c(C=O)c2)OC1(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LPL P06858 10/20 0.47
▸ LIPG Q9Y5X9 10/20 0.47
▸ EGFR P00533 1/20 0.41
▸ ROCK1 Q13464 1/20 0.41
▸ CA1 P00915 3/20 0.39
▸ CA2 P00918 3/20 0.39
▸ CA9 Q16790 3/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA3 P07451 1/20 0.39
▸ CA4 P22748 1/20 0.39
▸ CA6 P23280 1/20 0.39
▸ CA5A P35218 1/20 0.39
▸ CA7 P43166 1/20 0.39
▸ CA14 Q9ULX7 1/20 0.39
▸ CA5B Q9Y2D0 1/20 0.39
▸ IDO1 P14902 1/20 0.38
▸ TDO2 P48775 1/20 0.38
▸ P4HB P07237 1/20 0.37
▸ F2 P00734 1/20 0.36
▸ F11 P03951 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16041705 0.87 LPL (0.47) LPLLIPGEGFRROCK1CA1
SCHEMBL5781777 0.84 LPL (0.47) LPLLIPGEGFRROCK1CA1
SCHEMBL2279721 0.82 CA1 (0.43) LPLLIPGCA1CA2CA9
SCHEMBL17418959 0.82 LPL (0.42) LPLLIPGCA1CA2CA9
SCHEMBL29377126 0.81 ERN1 (0.49) LPLLIPGROCK1
SCHEMBL22465928 0.81 ERN1 (0.49) LPLLIPGROCK1
SCHEMBL12100015 0.81 ERN1 (0.44) LPLLIPGCA1CA2CA9
SCHEMBL31035643 0.81 CA1 (0.42) LPLLIPGCA1CA2CA9
SCHEMBL18981594 0.81 LPL (0.41) LPLLIPGEGFRCA1CA2
SCHEMBL14593477 0.80 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353874-A1 GLUCOCORTICOID RECEPTOR AGONISTS LILLY CO ELI (US) 2025-11-20 — — US disclosed
US-12404298-B2 Glucocorticoid receptor agonists ELI LILLY AND COMPANY (US) 2025-09-02 — — US disclosed
US-20240018182-A1 GLUCOCORTICOID RECEPTOR AGONISTS ELI LILLY AND COMPANY 2024-01-18 — — US disclosed
US-11787834-B2 Glucocorticoid receptor agonists ELI LILLY AND COMPANY (US) 2023-10-17 — — US disclosed
US-20220324904-A1 GLUCOCORTICOID RECEPTOR AGONISTS ELI LILLY AND COMPANY 2022-10-13 — — US disclosed
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 — — EP disclosed
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 — — EP disclosed
EP-2620439-A1 8-pyrazinyl-S-spiropyrimidinetrione-oxazinoquinoline derivatives as antibacterial agents PAH USA 15 LLC (US) 2013-07-31 — — EP disclosed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 — — EP disclosed
US-20090275536-A1 Antibacterial Agents PFIZER INC 2009-11-05 — — US disclosed
US-7557100-B2 Antibacterial agents PFIZER INC. (US) 2009-07-07 — — US disclosed
EP-1971612-A1 8-PYRAZINYL-S-SPIROPYRIMIDINETRIONE-OXAZINOQUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS Pfizer Products Inc. (US) 2008-09-24 — — EP disclosed
EP-1836174-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC. (US) 2007-09-26 — — EP disclosed
US-20070197518-A1 Antibacterial agents WARNER LAMBERT COMPANY LLC 2007-08-23 — — US disclosed
WO-2007072151-A1 8-PYRAZINYL-S-SPIROPYRIMIDINETRIONE-OXAZINOQUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS PFIZER PRODUCTS INC. (US) 2007-06-28 — — WO disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 — — US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 — — US disclosed
WO-2006039718-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2006-04-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12404298-B2 Glucocorticoid receptor agonists NR3C1, NR3C2, MC2R LPL 4401/4885LIPG 4415/4885EGFR 256/4885
US-20090275536-A1 Antibacterial Agents CLPP, MRPL21, SPOUT1 LPL 1022/4885LIPG 1064/4885EGFR 2752/4885
US-20240018182-A1 GLUCOCORTICOID RECEPTOR AGONISTS NR3C1, NR3C2, MC2R LPL 4401/4885LIPG 4415/4885EGFR 256/4885
US-20250353874-A1 GLUCOCORTICOID RECEPTOR AGONISTS NR3C1, NR3C2, MC2R LPL 4401/4885LIPG 4415/4885EGFR 256/4885
US-11787834-B2 Glucocorticoid receptor agonists NR3C1, NR3C2, MC2R LPL 4401/4885LIPG 4415/4885EGFR 256/4885
US-20220324904-A1 GLUCOCORTICOID RECEPTOR AGONISTS NR3C1, NR3C2, MC2R LPL 4401/4885LIPG 4415/4885EGFR 256/4885
US-20070197518-A1 Antibacterial agents CLPP, MRPL21, SPOUT1 LPL 1022/4885LIPG 1064/4885EGFR 2752/4885
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use MAP3K1, MAP3K5, MAP3K2 LPL 3851/4885LIPG 2157/4885EGFR 333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.